Concepts (160)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lymphoma, B-Cell | 5 | 2022 | 895 | 1.720 |
Why?
|
| Proto-Oncogene Proteins c-myc | 6 | 2022 | 810 | 1.290 |
Why?
|
| Lymphoma, Mantle-Cell | 2 | 2023 | 713 | 1.160 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 5 | 2022 | 1493 | 1.120 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 4 | 2023 | 1664 | 0.940 |
Why?
|
| Dermatitis Herpetiformis | 1 | 2022 | 6 | 0.900 |
Why?
|
| Translocation, Genetic | 4 | 2021 | 1245 | 0.770 |
Why?
|
| Gene Rearrangement | 3 | 2016 | 783 | 0.530 |
Why?
|
| In Situ Hybridization, Fluorescence | 6 | 2023 | 2232 | 0.520 |
Why?
|
| Genes, bcl-2 | 1 | 2014 | 166 | 0.480 |
Why?
|
| Immunohistochemistry | 8 | 2023 | 7548 | 0.440 |
Why?
|
| Immunophenotyping | 5 | 2015 | 1681 | 0.440 |
Why?
|
| Genes, myc | 1 | 2014 | 358 | 0.440 |
Why?
|
| Gene Rearrangement, B-Lymphocyte, Heavy Chain | 1 | 2011 | 41 | 0.410 |
Why?
|
| Chromosomes, Human, Pair 21 | 1 | 2012 | 104 | 0.410 |
Why?
|
| Genes, Immunoglobulin Heavy Chain | 1 | 2011 | 38 | 0.410 |
Why?
|
| Cyclin D1 | 3 | 2023 | 576 | 0.390 |
Why?
|
| Lymphoma, T-Cell, Peripheral | 1 | 2013 | 181 | 0.390 |
Why?
|
| Chromosomes, Human, Pair 18 | 1 | 2011 | 181 | 0.390 |
Why?
|
| Killer Cells, Natural | 2 | 2014 | 904 | 0.390 |
Why?
|
| Germinal Center | 1 | 2011 | 161 | 0.390 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2012 | 311 | 0.380 |
Why?
|
| Nose Neoplasms | 1 | 2013 | 229 | 0.370 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2011 | 272 | 0.370 |
Why?
|
| B-Lymphocytes | 2 | 2012 | 1294 | 0.340 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2013 | 489 | 0.320 |
Why?
|
| Biomarkers, Tumor | 5 | 2016 | 10331 | 0.270 |
Why?
|
| DNA-Binding Proteins | 2 | 2016 | 4821 | 0.260 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2016 | 3552 | 0.240 |
Why?
|
| SOXC Transcription Factors | 1 | 2023 | 53 | 0.230 |
Why?
|
| CD5 Antigens | 2 | 2015 | 112 | 0.230 |
Why?
|
| Prognosis | 7 | 2022 | 21713 | 0.210 |
Why?
|
| Cyclin D3 | 1 | 2021 | 23 | 0.200 |
Why?
|
| Cyclin D2 | 1 | 2021 | 40 | 0.200 |
Why?
|
| Neoplasm Grading | 2 | 2016 | 1742 | 0.180 |
Why?
|
| Phenotype | 4 | 2016 | 6295 | 0.170 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2012 | 2979 | 0.170 |
Why?
|
| Texas | 3 | 2016 | 6311 | 0.160 |
Why?
|
| Predictive Value of Tests | 3 | 2016 | 4892 | 0.150 |
Why?
|
| Rituximab | 1 | 2022 | 1528 | 0.150 |
Why?
|
| Aged, 80 and over | 8 | 2016 | 29902 | 0.150 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2016 | 6207 | 0.150 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2016 | 5539 | 0.150 |
Why?
|
| Adult | 10 | 2023 | 77950 | 0.150 |
Why?
|
| Chromosome Aberrations | 2 | 2015 | 1960 | 0.140 |
Why?
|
| Tennessee | 1 | 2016 | 36 | 0.140 |
Why?
|
| Adolescent | 5 | 2016 | 31252 | 0.140 |
Why?
|
| Young Adult | 5 | 2016 | 21445 | 0.140 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 1 | 2016 | 125 | 0.140 |
Why?
|
| Humans | 19 | 2023 | 261506 | 0.130 |
Why?
|
| Secretory Vesicles | 1 | 2014 | 39 | 0.130 |
Why?
|
| Neprilysin | 1 | 2014 | 66 | 0.130 |
Why?
|
| Chromosomes, Human | 1 | 2015 | 295 | 0.120 |
Why?
|
| Aged | 9 | 2016 | 70117 | 0.120 |
Why?
|
| Antigens, Nuclear | 1 | 2013 | 119 | 0.110 |
Why?
|
| Genome-Wide Association Study | 1 | 2021 | 2265 | 0.110 |
Why?
|
| DNA End-Joining Repair | 1 | 2013 | 86 | 0.110 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2012 | 6915 | 0.110 |
Why?
|
| Middle Aged | 9 | 2016 | 86204 | 0.110 |
Why?
|
| Immunity, Cellular | 1 | 2014 | 419 | 0.110 |
Why?
|
| Cell Proliferation | 3 | 2013 | 7226 | 0.100 |
Why?
|
| Karyotyping | 1 | 2013 | 1022 | 0.100 |
Why?
|
| Ki-67 Antigen | 1 | 2013 | 666 | 0.100 |
Why?
|
| In Situ Hybridization | 1 | 2013 | 1037 | 0.090 |
Why?
|
| Male | 10 | 2016 | 123000 | 0.090 |
Why?
|
| RNA, Viral | 1 | 2013 | 671 | 0.090 |
Why?
|
| Lymphoma, Follicular | 1 | 2015 | 587 | 0.090 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2 | 2015 | 2527 | 0.090 |
Why?
|
| Up-Regulation | 1 | 2016 | 2450 | 0.090 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 1 | 2012 | 301 | 0.080 |
Why?
|
| Female | 10 | 2016 | 141928 | 0.080 |
Why?
|
| Herpesvirus 4, Human | 1 | 2013 | 966 | 0.080 |
Why?
|
| Homeostasis | 1 | 2013 | 950 | 0.080 |
Why?
|
| Biopsy | 1 | 2016 | 3443 | 0.080 |
Why?
|
| Anemia | 1 | 2012 | 689 | 0.070 |
Why?
|
| Bone Marrow Purging | 1 | 2006 | 86 | 0.070 |
Why?
|
| Survival Rate | 3 | 2015 | 12221 | 0.070 |
Why?
|
| Th1 Cells | 1 | 2006 | 250 | 0.060 |
Why?
|
| Cell Separation | 1 | 2006 | 612 | 0.060 |
Why?
|
| Multiple Myeloma | 1 | 2014 | 2138 | 0.060 |
Why?
|
| Time Factors | 2 | 2015 | 12926 | 0.050 |
Why?
|
| Transplantation, Autologous | 1 | 2006 | 1914 | 0.050 |
Why?
|
| Combined Modality Therapy | 1 | 2013 | 8865 | 0.050 |
Why?
|
| Leukemia, Myeloid | 1 | 2006 | 941 | 0.050 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2022 | 15862 | 0.050 |
Why?
|
| K562 Cells | 2 | 2014 | 338 | 0.050 |
Why?
|
| Dendritic Cells | 1 | 2006 | 1085 | 0.040 |
Why?
|
| Microsatellite Repeats | 1 | 2001 | 575 | 0.040 |
Why?
|
| Stem Cell Transplantation | 1 | 2006 | 1360 | 0.040 |
Why?
|
| Risk Factors | 1 | 2016 | 17523 | 0.040 |
Why?
|
| Colorectal Neoplasms | 1 | 2013 | 3578 | 0.040 |
Why?
|
| Neoplasm Staging | 1 | 2013 | 13658 | 0.040 |
Why?
|
| Interleukin-6 | 3 | 2013 | 1038 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2013 | 1538 | 0.030 |
Why?
|
| Natural Cytotoxicity Triggering Receptor 3 | 1 | 2014 | 9 | 0.030 |
Why?
|
| Mutation | 2 | 2013 | 15179 | 0.030 |
Why?
|
| Monocytes | 2 | 2006 | 788 | 0.030 |
Why?
|
| Treatment Outcome | 1 | 2016 | 32848 | 0.030 |
Why?
|
| Flow Cytometry | 2 | 2015 | 3033 | 0.030 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily K | 1 | 2014 | 56 | 0.030 |
Why?
|
| Adenocarcinoma | 1 | 2013 | 7789 | 0.030 |
Why?
|
| Granzymes | 1 | 2014 | 91 | 0.030 |
Why?
|
| Ku Autoantigen | 1 | 2013 | 79 | 0.030 |
Why?
|
| Caspase 3 | 1 | 2014 | 471 | 0.030 |
Why?
|
| Cells, Cultured | 3 | 2013 | 5637 | 0.030 |
Why?
|
| Child | 1 | 2014 | 29154 | 0.030 |
Why?
|
| Disease-Free Survival | 2 | 2015 | 10001 | 0.030 |
Why?
|
| Colonic Neoplasms | 1 | 2001 | 1390 | 0.030 |
Why?
|
| Gene Amplification | 1 | 2015 | 731 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2013 | 528 | 0.030 |
Why?
|
| Fetal Blood | 1 | 2014 | 482 | 0.020 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2015 | 551 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2015 | 1217 | 0.020 |
Why?
|
| Cell Transformation, Viral | 1 | 1991 | 138 | 0.020 |
Why?
|
| Cellular Senescence | 1 | 2013 | 382 | 0.020 |
Why?
|
| Antigens, CD | 2 | 2006 | 1385 | 0.020 |
Why?
|
| Wnt Signaling Pathway | 1 | 2013 | 430 | 0.020 |
Why?
|
| HIV | 1 | 1991 | 229 | 0.020 |
Why?
|
| Reactive Oxygen Species | 1 | 2014 | 987 | 0.020 |
Why?
|
| Colon | 1 | 2013 | 670 | 0.020 |
Why?
|
| Interleukin-1 | 2 | 2006 | 461 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2011 | 37905 | 0.020 |
Why?
|
| Placenta | 1 | 1991 | 516 | 0.020 |
Why?
|
| Carcinogenesis | 1 | 2013 | 1026 | 0.020 |
Why?
|
| Lipopolysaccharide Receptors | 1 | 2006 | 86 | 0.020 |
Why?
|
| Epithelial Cells | 1 | 2013 | 1818 | 0.020 |
Why?
|
| Receptors, Chemokine | 1 | 2006 | 114 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2015 | 6009 | 0.020 |
Why?
|
| DNA Damage | 1 | 2013 | 1954 | 0.020 |
Why?
|
| Phagocytosis | 1 | 2006 | 260 | 0.020 |
Why?
|
| Antigen-Presenting Cells | 1 | 2006 | 284 | 0.020 |
Why?
|
| Antigens, CD34 | 1 | 2006 | 593 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2013 | 5710 | 0.010 |
Why?
|
| Linear Models | 1 | 2006 | 1085 | 0.010 |
Why?
|
| Cytokines | 1 | 1991 | 2809 | 0.010 |
Why?
|
| Imatinib Mesylate | 1 | 2006 | 1665 | 0.010 |
Why?
|
| Interferon-gamma | 1 | 2006 | 1144 | 0.010 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2006 | 607 | 0.010 |
Why?
|
| Lymphocyte Activation | 1 | 2006 | 1688 | 0.010 |
Why?
|
| Acute Disease | 1 | 2006 | 2422 | 0.010 |
Why?
|
| Benzamides | 1 | 2006 | 1832 | 0.010 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2006 | 1016 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2013 | 3869 | 0.010 |
Why?
|
| CD3 Complex | 1 | 2001 | 314 | 0.010 |
Why?
|
| Statistics as Topic | 1 | 2001 | 445 | 0.010 |
Why?
|
| Cell Survival | 1 | 2006 | 3045 | 0.010 |
Why?
|
| Lymphocyte Count | 1 | 2001 | 486 | 0.010 |
Why?
|
| Cyclophosphamide | 1 | 2006 | 3001 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2006 | 5395 | 0.010 |
Why?
|
| Leukemia | 1 | 2006 | 1635 | 0.010 |
Why?
|
| Piperazines | 1 | 2006 | 2101 | 0.010 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2001 | 992 | 0.010 |
Why?
|
| Pyrimidines | 1 | 2006 | 3518 | 0.010 |
Why?
|
| Mice | 1 | 2013 | 34495 | 0.010 |
Why?
|
| Phytohemagglutinins | 1 | 1991 | 71 | 0.010 |
Why?
|
| Endotoxins | 1 | 1991 | 96 | 0.010 |
Why?
|
| Animals | 1 | 2013 | 59536 | 0.000 |
Why?
|
| Kinetics | 1 | 1991 | 2049 | 0.000 |
Why?
|
| Escherichia coli | 1 | 1991 | 1203 | 0.000 |
Why?
|
| Antineoplastic Agents | 1 | 2006 | 14289 | 0.000 |
Why?
|